GBM-MR-NER-Outcomes | Outcome Prediction in Patients with Glioblastoma by Using Imaging, Clinical, and Genomic Biomarkers: Focus on the Nonenhancing Component of the Tumor

DOI: 10.7937/K9/TCIA.2014.FAB7YRPZ | Data Citation Required | Analysis Result

Summary

This manuscript correlates patient survival with morphologic imaging features and hemodynamic parameters obtained from the nonenhancing region (NER) of glioblastoma (GBM), along with clinical and genomic markers. Forty-five patients with GBM underwent baseline imaging with contrast material-enhanced magnetic resonance (MR) imaging and dynamic susceptibility contrast-enhanced T2*-weighted perfusion MR imaging.  See DSC T2* MR Perfusion Analysis for more information about the authors’ perfusion analysis.  Molecular and clinical predictors of survival were obtained. Single and multivariable models of overall survival (OS) and progression-free survival (PFS) were explored with Kaplan-Meier estimates, Cox regression, and random survival forests.

Worsening OS (log-rank test, P = .0103) and PFS (log-rank test, P = .0223) were associated with increasing relative cerebral blood volume of NER (rCBV NER ), which was higher with deep white matter involvement (t test, P = .0482) and poor NER margin definition (t test, P = .0147). NER crossing the midline was the only morphologic feature of NER associated with poor survival (log-rank test, P = .0125). Preoperative Karnofsky performance score (KPS) and resection extent (n = 30) were clinically significant OS predictors (log-rank test, P = .0176 and P = .0038, respectively). No genomic alterations were associated with survival, except patients with high rCBV NER  and wild-type epidermal growth factor receptor (EGFR) mutation had significantly poor survival (log-rank test, P = .0306; area under the receiver operating characteristic curve = 0.62). Combining resection extent with rCBV NER  marginally improved prognostic ability (permutation, P = .084). Random forest models of presurgical predictors indicated rCBV NER  as the top predictor; also important were KPS, age at diagnosis, and NER crossing the midline. A multivariable model containing rCBV NER , age at diagnosis, and KPS can be used to group patients with more than 1 year of difference in observed median survival (0.49-1.79 years). Conclusion Patients with high rCBV NER  and NER crossing the midline and those with high rCBV NER  and wild-type EGFR mutation showed poor survival. In multivariable survival models, however, rCBV NER  provided unique prognostic information that went above and beyond the assessment of all NER imaging features, as well as clinical and genomic features.

Data Access

Some data in this collection contains images that could potentially be used to reconstruct a human face. To safeguard the privacy of participants, users must sign and submit a TCIA Restricted License Agreement to help@cancerimagingarchive.net before accessing the data.

 

Version 1: Updated 2014/07/24

Collections Used In This Analysis Result

Citations & Data Usage Policy

Data Citation Required: Users must abide by the TCIA Data Usage Policy and Restrictions. Attribution must include the following citation, including the Digital Object Identifier:

Collections Used In This Analysis Result